sample_name,pass_qc,cell_line,library,patient_id,pharmacoscopy_id,old_patient_id,sample_id,atac_seq_batch,experiment_name,organism,data_source,flowcell,lane,BSF_name,clinical_centre,sample_type,cell_type,sample_origin,timepoint,experiment,ibrutinib_cohort,timepoint_name,treatment_dosage,PI+/Ax-,PI+/Ax+,PI-/Ax-,PI-/Ax+,CD19/CD5,treatment_response,patient_clinician,patient_initials,patient_gender,patient_birth_date,patient_death_date,patient_last_checkup_date,diagnosis_date,diagnosis_disease,hospital,diagnosis_change_date,diagnosis_stage_rai,diagnosis_stage_binet,under_treatment,under_concurrent_treatment,concurrent_treatment_regimen,concurrent_treatment_date,concurrent_treatment_response,concurrent_treatment_end,treatment_date,treatment_regimen,treatment_response.1,treatment_end_date,relapse,treatment_1_date,treatment_1_regimen,treatment_1_duration,treatment_1_response,treatment_2_date,treatment_2_regimen,treatment_2_duration,treatment_2_response,treatment_3_date,treatment_3_regimen,treatment_3_duration,treatment_3_response,treatment_4_date,treatment_4_regimen,treatment_4_response,treatment_end_date,ighv_gene,ighv_homology,ighv_mutation_status,CD38_cells_percentage,CD38_positive,CD38_measurement_date,CD38_changed,ZAP70_cells_percentage,ZAP70_positive,ZAP70_monoallelic_methylation,CD49d_cells_percentage,CD49d_positive,sample_collection_date,storage_condition,lymp_count,%CLL_cells,mutations,sample_shippment_batch,sample_cell_number,sample_processing_date,sample_viability
CLL_ATAC-seq_CLL1_M4687_post,1,CLL,ATAC-seq,CLL1,GB398,AKH2,M4687,ATAC39,ATAC39s7,human,bsf,BSF_0197_H5JTNBBXX,2,CLL_ATACseq_M4687_M4687_ATAC39s7,vienna,patient,CLL,in_vivo,2,AKH2-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,03/05/1959,,26/04/2013,22/03/2011,CLL,AKH,,II,B,1,,,,,,15/01/2013,,,,,15/01/2013,,,,,,,,,,,,,,,,,100,0,93,1,22/03/2011,,,,,,,07/03/2013,,7.3,,,,5000000,,95.64
CLL_ATAC-seq_CLL1_M4732_pre,1,CLL,ATAC-seq,CLL1,GB402,AKH2,M4732,ATAC39,ATAC39s6,human,bsf,BSF_0197_H5JTNBBXX,2,CLL_ATACseq_M4732_M4732_ATAC39s6,vienna,patient,CLL,in_vivo,1,AKH2-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,03/05/1959,,26/04/2013,22/03/2011,CLL,AKH,,II,B,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,100,0,93,1,22/03/2011,,,,,,,14/01/2013,,15.3,,"del13 (84%), del11q (94%)",,5000000,,66.47
CLL_ATAC-seq_CLL10_M4684_pre,1,CLL,ATAC-seq,CLL10,GB500,AKH12,M4684,ATAC40,ATAC40s16,human,bsf,BSF_0197_H5JTNBBXX,7,CLL_ATACseq_M4684_M4684_ATAC40s16,vienna,patient,CLL,in_vivo,1,AKH12-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,02/03/1942,,10/04/2014,01/01/1999,CLL,AKH,,IV,C,0,,,,,,,,PR,,,,,,,,,,,,,,,,,,,,100,0,3,0,21/01/2013,,,,,,,18/02/2013,,9,,del11q (88%),,5000000,,96.37
CLL_ATAC-seq_CLL10_M4688_post,1,CLL,ATAC-seq,CLL10,GB501,AKH12,M4688,ATAC40,ATAC40s17,human,bsf,BSF_0197_H5JTNBBXX,7,CLL_ATACseq_M4688_M4688_ATAC40s17,vienna,patient,CLL,in_vivo,2,AKH12-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,02/03/1942,,10/04/2014,01/01/1999,CLL,AKH,,IV,C,1,,,,,,10/11/2014,,,,,10/11/2014,,,,,,,,,,,,,,,,,100,0,3,0,21/01/2013,,,,,,,25/03/2013,,26,,,,5000000,,94.47
CLL_ATAC-seq_CLL11_M4703_pre,1,CLL,ATAC-seq,CLL11,,AKH14,M4703,ATAC40,ATAC40s23,human,bsf,BSF_0197_H5JTNBBXX,7,CLL_ATACseq_M4703_M4703_ATAC40s23,vienna,patient,CLL,in_vivo,1,AKH14-Ibrutinib,1,before Ibrutinib,,,,,,,,,,F,04/05/1938,,19/08/2014,01/01/2006,CLL,AKH,,IV,C,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,91,1,1,0,24/04/2013,,,,,,,19/08/2014,,67,,"del13p (80% no signal), del17p (90%)",,5000000,,96.03
CLL_ATAC-seq_CLL11_M4723_post,1,CLL,ATAC-seq,CLL11,,AKH14,M4723,ATAC59,ATAC59s2,human,bsf,,,,vienna,patient,CLL,in_vivo,2,AKH14-Ibrutinib,1,after Ibrutinib,,,,,,,,,,F,04/05/1938,,19/08/2014,01/01/2006,CLL,AKH,,IV,C,1,,,,,,22/03/2015,,,,,22/03/2015,,,,,,,,,,,,,,,,,91,1,1,0,24/04/2013,,,,,,,29/04/2015,,38.27,,,,5000000,,95.71
CLL_ATAC-seq_CLL12_M4717_pre,1,CLL,ATAC-seq,CLL12,GB397 ,AKH16,M4717,ATAC43,ATAC43s3,human,bsf,BSF_0207_H5JL7BBXX,5,CLL_ATACseq_M4717_M4717_ATAC43s3_S12645,vienna,patient,CLL,in_vivo,1,AKH16-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,02/11/1943,,10/04/2014,20/2/2002,CLL,AKH,,IV,C,0,,,,,,,,PR,,,,,,,,,,,,,,,,,,,,100,0,66,1,20/02/2002,,,,,,,05/02/2015,,115,,normal,,5000000,,95.15
CLL_ATAC-seq_CLL12_M4721_post,1,CLL,ATAC-seq,CLL12,GB396 ,AKH16,M4721,ATAC43,ATAC43s4,human,bsf,BSF_0207_H5JL7BBXX,5,CLL_ATACseq_M4721_M4721_ATAC43s4_S12646,vienna,patient,CLL,in_vivo,2,AKH16-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,02/11/1943,,10/04/2014,20/2/2002,CLL,AKH,,IV,C,1,,,,,,26/06/2014,,,14/08/2015,,26/06/2014,,,,,,,,,,,,,,,,,100,0,66,1,20/02/2002,,,,,,,28/04/2015,,112,,,,5000000,,92.27
CLL_ATAC-seq_CLL13_M4701_pre,1,CLL,ATAC-seq,CLL13,,AKH17,M4701,ATAC43,ATAC43s5,human,bsf,BSF_0207_H5JL7BBXX,5,CLL_ATACseq_M4701_M4701_ATAC43s5_S12647,vienna,patient,CLL,in_vivo,1,AKH17-Ibrutinib,1,before Ibrutinib,,,,,,,,,,F,03/08/1954,,25/05/2014,01/02/2004,CLL,AKH,,II,B,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,100,0,73,1,18/04/2013,,,,,,,26/06/2014,,103,,del13p (60%),,5000000,,97.16
CLL_ATAC-seq_CLL13_M4711_post,1,CLL,ATAC-seq,CLL13,,AKH17,M4711,ATAC43,ATAC43s6,human,bsf,BSF_0207_H5JL7BBXX,5,CLL_ATACseq_M4711_M4711_ATAC43s6_S12648,vienna,patient,CLL,in_vivo,2,AKH17-Ibrutinib,1,after Ibrutinib,,,,,,,,,,F,03/08/1954,alive,25/05/2014,01/02/2004,CLL,AKH,,II,B,1,,,,,,08/05/2014,,,16/01/2015,,08/05/2014,,,,,,,,,,,,,,,,,100,0,73,1,18/04/2013,,,,,,,09/12/2014,,15.48,,,,5000000,,94.48
CLL_ATAC-seq_CLL14_M4697_pre,1,CLL,ATAC-seq,CLL14,,AKH18,M4697,ATAC43,ATAC43s7,human,bsf,BSF_0207_H5JL7BBXX,5,CLL_ATACseq_M4697_M4697_ATAC43s7_S12649,vienna,patient,CLL,in_vivo,1,AKH18-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,15/08/1954,21/05/2015,09/04/2015,01/09/2000,CLL,AKH,,II,B,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,91,1,1,0,14/01/2013,,,,,,,23/04/2014,,97.5,,"del13p (92% no signal), del17p (75%)",,5000000,,97.25
CLL_ATAC-seq_CLL14_M4700_post,1,CLL,ATAC-seq,CLL14,,AKH18,M4700,ATAC43,ATAC43s8,human,bsf,BSF_0207_H5JL7BBXX,5,CLL_ATACseq_M4700_M4700_ATAC43s8_S12650,vienna,patient,CLL,in_vivo,2,AKH18-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,15/08/1954,21/05/2015,09/04/2015,01/09/2000,CLL,AKH,,II,B,1,,,,,,10/03/2015,,,,,10/03/2015,,,,,,,,,,,,,,,,,91,1,1,0,14/01/2013,,,,,,,17/06/2014,,309,,,,5000000,,91.65
CLL_ATAC-seq_CLL15_M4720_pre,1,CLL,ATAC-seq,CLL15,GB399,AKH19,M4720,ATAC42,ATAC42s1,human,bsf,BSF_0221_H5WWTBBXX,7,CLL_ATACseq_M4720_M4720_ATAC42s1_S14042,vienna,patient,CLL,in_vivo,1,AKH19-Ibrutinib,1,before Ibrutinib,,,,,,,,,,F,15/02/1932,,09/05/2014,01/01/2006,CLL,AKH,,I,A,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,95,1,8,0,05/07/2006,,,,,,,10/03/2015,,280,,"del13q (68,5%) ",,5000000,,96.54
CLL_ATAC-seq_CLL15_M4724_post,1,CLL,ATAC-seq,CLL15,GB392 ,AKH19,M4724,ATAC42,ATAC42s2,human,bsf,BSF_0221_H5WWTBBXX,7,CLL_ATACseq_M4724_M4724_ATAC42s2_S14043,vienna,patient,CLL,in_vivo,2,AKH19-Ibrutinib,1,after Ibrutinib,,,,,,,,,,F,15/02/1932,,09/05/2014,01/01/2006,CLL,AKH,,I,A,1,,,,,,19/03/2015,,,,,19/03/2015,,,,,,,,,,,,,,,,,95,1,8,0,05/07/2006,,,,,,,05/05/2015,,277,,,,5000000,,93.46
CLL_ATAC-seq_CLL19_M4521_pre,1,CLL,ATAC-seq,CLL19,,AKH4,M4521,ATAC39,ATAC39s13,human,bsf,BSF_0197_H5JTNBBXX,2,CLL_ATACseq_M4521_M4521_ATAC39s13,vienna,patient,CLL,in_vivo,3,AKH4-Zydelig,1,before Ibrutinib,,,,,,,,,,M,07/07/1949,,08/10/2015,01/10/1996,CLL,AKH,,II,B,1,,,,,,17/03/2015,,,,,17/03/2015,,,,,,,,,,,,,,,,,100,0,33,1,18/07/2013,,,,,,,17/03/2015,,203,,,,5000000,,93.18
CLL_ATAC-seq_CLL19_M4552_post,1,CLL,ATAC-seq,CLL19,,AKH4,M4552,ATAC39,ATAC39s14,human,bsf,BSF_0197_H5JTNBBXX,2,CLL_ATACseq_M4552_M4552_ATAC39s14,vienna,patient,CLL,in_vivo,5,AKH4-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,07/07/1949,,08/10/2015,01/10/1996,CLL,AKH,,II,B,1,,,,,,27/09/2011,,,27/02/2012,,27/09/2011,,,,,,,,,,,,,,,,,100,0,33,1,18/07/2013,,,,,,,19/05/2015,,137,,,,5000000,,92
CLL_ATAC-seq_CLL2_M4683_post,1,CLL,ATAC-seq,CLL2,GB499,AKH3,M4683,ATAC39,ATAC39s9,human,bsf,BSF_0197_H5JTNBBXX,2,CLL_ATACseq_M4683_M4683_ATAC39s9,vienna,patient,CLL,in_vivo,2,AKH3-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,30/09/1953,,13/10/2015,01/02/2007,CLL,AKH,,I,A,1,,,,,,01/09/2014,,,,,01/09/2014,,,,,,,,,,,,,,,,,100,0,2,0,19/02/2007,,,,,,,12/02/2013,,73,,,,5000000,,95.86
CLL_ATAC-seq_CLL2_M4733_pre,1,CLL,ATAC-seq,CLL2,GB502,AKH3,M4733,ATAC39,ATAC39s8,human,bsf,BSF_0197_H5JTNBBXX,2,CLL_ATACseq_M4733_M4733_ATAC39s8,vienna,patient,CLL,in_vivo,1,AKH3-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,30/09/1953,,13/10/2015,01/02/2007,CLL,AKH,,I,A,0,,,,,,,,PR,,,,,,,,,,,,,,,,,,,,100,0,2,0,19/02/2007,,,,,,,07/01/2013,,61,,"del13 (80%, del17p (85%)",,5000000,,89.45
CLL_ATAC-seq_CLL20_M4692_pre,1,CLL,ATAC-seq,CLL20,,AKH13,M4692,ATAC40,ATAC40s18,human,bsf,BSF_0197_H5JTNBBXX,7,CLL_ATACseq_M4692_M4692_ATAC40s18,vienna,patient,CLL,in_vivo,4,AKH13-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,08/06/1955,,31/03/2014,01/03/2008,CLL,AKH,,II,B,1,,,,,,28/11/2013,,SD,25/03/2015,,28/11/2013,,,,,,,,,,,,,,,,,,,14,0,27/09/2011,,,,,,,12/12/2013,,208,,,,5000000,,93.36
CLL_ATAC-seq_CLL20_M4694_post,1,CLL,ATAC-seq,CLL20,,AKH13,M4694,ATAC40,ATAC40s19,human,bsf,BSF_0197_H5JTNBBXX,7,CLL_ATACseq_M4694_M4694_ATAC40s19,vienna,patient,CLL,in_vivo,5,AKH13-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,08/06/1955,,31/03/2014,01/03/2008,CLL,AKH,,II,B,1,,,,,,28/11/2013,,SD,25/03/2015,,28/11/2013,,,,,,,,,,,,,,,,,,,14,0,27/09/2011,,,,,,,17/01/2014,,154,,normal,,5000000,,94.54
CLL_ATAC-seq_CLL21_M4537_post,1,CLL,ATAC-seq,CLL21,,AKH15,M4537,ATAC43,ATAC43s2,human,bsf,BSF_0207_H5JL7BBXX,5,CLL_ATACseq_M4537_M4537_ATAC43s2_S12644,vienna,patient,CLL,in_vivo,6,AKH15-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,18/06/1952,,15/05/2014,01/04/2008,CLL,AKH,,IV,C,1,,,,,,13/11/2013,,,12/12/2014,,13/11/2013,,,,,,,,,,,,,,,,,100,0,19,0,04/11/2008,,,,,,,23/04/2015,,8.6,,,,5000000,,89.32
CLL_ATAC-seq_CLL21_M4707_pre,1,CLL,ATAC-seq,CLL21,,AKH15,M4707,ATAC43,ATAC43s1,human,bsf,BSF_0207_H5JL7BBXX,5,CLL_ATACseq_M4707_M4707_ATAC43s1_S12643,vienna,patient,CLL,in_vivo,5,AKH15-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,18/06/1952,,15/05/2014,01/04/2008,CLL,AKH,,IV,C,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,100,0,19,0,04/11/2008,,,,,,,27/11/2014,,13.4,,,,5000000,,97.18
CLL_ATAC-seq_CLL3_M4702_pre,1,CLL,ATAC-seq,CLL3,GB401,AKH5,M4702,ATAC40,ATAC40s1,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4702_M4702_ATAC40s1,vienna,patient,CLL,in_vivo,1,AKH5-Ibrutinib,1,before Ibrutinib,,,,,,,,,,F,06/07/1940,,25/04/2014,29/03/2004,CLL,AKH,,I,A,0,,,,,,,,PR,,,,,,,,,,,,,,,,,,,,100,0,33,1,17/07/2014,,,,,,,17/07/2014,,186,,"del17p (12%), tri12 (54%)",,5000000,,98.24
CLL_ATAC-seq_CLL3_M4706_post,1,CLL,ATAC-seq,CLL3,GB400,AKH5,M4706,ATAC40,ATAC40s2,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4706_M4706_ATAC40s2,vienna,patient,CLL,in_vivo,2,AKH5-Ibrutinib,1,after Ibrutinib,,,,,,,,,,F,06/07/1940,,25/04/2014,29/03/2004,CLL,AKH,,I,A,1,,,,,,26/02/2015,,,,,26/02/2015,,,,,,,,,,,,,,,,,100,0,33,1,17/07/2014,,,,,,,11/11/2014,,39,,,,5000000,,96.38
CLL_ATAC-seq_CLL4_M4716_pre,1,CLL,ATAC-seq,CLL4,,AKH6,M4716,ATAC40,ATAC40s3,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4716_M4716_ATAC40s3,vienna,patient,CLL,in_vivo,1,AKH6-Ibrutinib,1,before Ibrutinib,,,,,,,,,,F,11/03/1943,,06/06/2014,01/01/2006,CLL,AKH,,I,A,0,,,,,,,,PR,,,,,,,,,,,,,,,,,,,,95,1,7,0,04/02/2008,,,,,,,03/02/2015,,30.86,,"del13q (10%), tri12 (42%)",,2800000,,
CLL_ATAC-seq_CLL4_M4726_post,1,CLL,ATAC-seq,CLL4,,AKH6,M4726,ATAC40,ATAC40s4,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4726_M4726_ATAC40s4,vienna,patient,CLL,in_vivo,2,AKH6-Ibrutinib,1,after Ibrutinib,,,,,,,,,,F,11/03/1943,,06/06/2014,01/01/2006,CLL,AKH,,I,A,1,,,,,,28/01/2013,,,,,28/01/2013,,,,,,,,,,,,,,,,,95,1,7,0,04/02/2008,,,,,,,26/05/2015,,5.61,,,,5000000,,91.46
CLL_ATAC-seq_CLL5_M4685_post,1,CLL,ATAC-seq,CLL5,GB395 ,AKH7,M4685,ATAC40,ATAC40s6,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4685_M4685_ATAC40s6,vienna,patient,CLL,in_vivo,2,AKH7-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,29/04/1952,,29/10/2015,01/01/2005,CLL,AKH,,I,A,1,,,,,,16/10/2014,,,,,16/10/2014,,,,,,,,,,,,,,,,,100,0,90,1,14/01/2013,,,,,,,25/02/2013,,28,,,,5000000,,97.17
CLL_ATAC-seq_CLL5_M4734_pre,1,CLL,ATAC-seq,CLL5,GB403,AKH7,M4734,ATAC40,ATAC40s5,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4734_M4734_ATAC40s5,vienna,patient,CLL,in_vivo,1,AKH7-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,29/04/1952,,29/10/2015,01/01/2005,CLL,AKH,,I,A,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,100,0,90,1,14/01/2013,,,,,,,21/01/2013,,243,,"del13p (79%), del17p (86%)",,5000000,,92.65
CLL_ATAC-seq_CLL6_M4704_pre,1,CLL,ATAC-seq,CLL6,GB394 ,AKH8,M4704,ATAC40,ATAC40s7,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4704_M4704_ATAC40s7,vienna,patient,CLL,in_vivo,1,AKH8-Ibrutinib,1,before Ibrutinib,,,,,,,,,,F,13/07/1939,,27/08/2013,01/01/1987,CLL,AKH,,IV,C,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,,,76,1,07/06/2013,,,,,,,16/10/2014,,270,,"del13p (87%), del17p (87%)",,5000000,,97.39
CLL_ATAC-seq_CLL6_M4708_post,1,CLL,ATAC-seq,CLL6,GB393 ,AKH8,M4708,ATAC40,ATAC40s8,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4708_M4708_ATAC40s8,vienna,patient,CLL,in_vivo,2,AKH8-Ibrutinib,1,after Ibrutinib,,,,,,,,,,F,13/07/1939,,27/08/2013,01/01/1987,CLL,AKH,,IV,C,1,,,,,,23/12/2014,,,,,23/12/2014,,,,,,,,,,,,,,,,,,,76,1,07/06/2013,,,,,,,27/11/2014,,189,,,,5000000,,95.37
CLL_ATAC-seq_CLL7_M4714_pre,1,CLL,ATAC-seq,CLL7,GB505,AKH9,M4714,ATAC40,ATAC40s9,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4714_M4714_ATAC40s9,vienna,patient,CLL,in_vivo,1,AKH9-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,30/01/1951,,23/05/2013,29/03/2011,CLL,AKH,,IV,C,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,100,0,66,1,29/03/2011,,,,,,,22/12/2014,,72.6,,del13p (80%),,5000000,,96.89
CLL_ATAC-seq_CLL7_M4715_post,1,CLL,ATAC-seq,CLL7,GB506,AKH9,M4715,ATAC40,ATAC40s10,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4715_M4715_ATAC40s10,vienna,patient,CLL,in_vivo,2,AKH9-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,30/01/1951,,23/05/2013,29/03/2011,CLL,AKH,,IV,C,1,,,,,,20/10/2014,,,,,20/10/2014,,,,,,,,,,,,,,,,,100,0,66,1,29/03/2011,,,,,,,15/01/2015,,40.4,,,,5000000,,97.85
CLL_ATAC-seq_CLL8_M4705_pre,1,CLL,ATAC-seq,CLL8,GB504,AKH10,M4705,ATAC40,ATAC40s11,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4705_M4705_ATAC40s11,vienna,patient,CLL,in_vivo,1,AKH10-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,12/08/1930,6/6/2015,12/09/2013,,CLL,AKH,,II,B,0,,,,,,,,PR,,,,,,,,,,,,,,,,,,,,96,1,,,,,,,,,,20/10/2014,,,,del17p (70%),,5000000,,96.45
CLL_ATAC-seq_CLL8_M4710_post,1,CLL,ATAC-seq,CLL8,GB493,AKH10,M4710,ATAC40,ATAC40s12,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4710_M4710_ATAC40s12,vienna,patient,CLL,in_vivo,2,AKH10-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,12/08/1930,,12/09/2013,,CLL,AKH,,II,B,1,,,,,,29/07/2014,,,15/04/2015,,29/07/2014,,,,,,,,,,,,,,,,,96,1,,,,,,,,,,09/12/2014,,,,,,5000000,,90.87
CLL_ATAC-seq_CLL9_M4696_pre,1,CLL,ATAC-seq,CLL9,GB494,AKH11,M4696,ATAC40,ATAC40s14,human,bsf,BSF_0197_H5JTNBBXX,6,CLL_ATACseq_M4696_M4696_ATAC40s14,vienna,patient,CLL,in_vivo,2,AKH11-Ibrutinib,1,before Ibrutinib,,,,,,,,,,M,23/12/1954,,11/04/2014,01/12/2006,CLL,AKH,,IV,C,0,,,,,,,,SD,,,,,,,,,,,,,,,,,,,,91,1,2,0,01/12/2006,,,,,,,11/04/2014,,46,,normal,,5000000,,96.08
CLL_ATAC-seq_CLL9_M4728_post,1,CLL,ATAC-seq,CLL9,GB495,AKH11,M4728,ATAC40,ATAC40s15,human,bsf,BSF_0197_H5JTNBBXX,7,CLL_ATACseq_M4728_M4728_ATAC40s15,vienna,patient,CLL,in_vivo,3,AKH11-Ibrutinib,1,after Ibrutinib,,,,,,,,,,M,23/12/1954,,11/04/2014,01/12/2006,CLL,AKH,,IV,C,1,,,,,,18/02/2013,,,01/08/2013,,18/02/2013,,,,,,,,,,,,,,,,,91,1,2,0,01/12/2006,,,,,,,22/07/2015,,16.84,,,,5000000,,94.94
